An observational study in Valvular Heart Disease, sponsored by French Cardiology Society. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by French Cardiology Society · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Heart Valve Diseases with a site in France — 16 open to participants now, 22 under way, 1 of them phase 3. Heart Valve Diseases · France.
Among the 48 studies in Heart Valve Diseases with a site in France, this one is the 8th largest by planned enrollment of the 17 observational ones that give a count, is one of 3 that started in 2025, is one of 17 observational ones, reaches primary completion later than 15 of the 21 other live ones, and was the 47th registered.
557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.
Browse Heart Valve Diseases studies →16 of the 48 studies in Heart Valve Diseases with a site in France are open now. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 65+ · Healthy volunteers
Abbott Medical Devices · Sites in France, United States, Denmark and 7 more countries
Montreal Heart Institute · Sites in France, United States, Canada and 2 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3
First in 2002; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 1,000 is above the median of 300 across 228 observational studies indexed under Heart Valve Diseases.
Median enrollment 228 across the 31 interventional studies, 800 across the 17 observational. Of the 25 that completed or were terminated, 8 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 48 have an industry lead sponsor. The 10 most frequent:
French Cardiology Society is the lead sponsor of 85 studies on the registry; 16 are open to participants now.
French Cardiology Society has 1 study filed under Heart Valve Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Heart Valve Diseases with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06215378Phase 3Assistance Publique - Hôpitaux de ParisAntagonization of Heparin With Protamine Sulfate After TAVI | 2027-03-01 |
| NCT02747485Assistance Publique Hopitaux De MarseilleImpact of Diffuse Myocardial Fibrosis on the Ventricular Function in Regurgitant Left-Sided Valve Heart Diseases ( The DIFFUsE Study) | 2026-11 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 48 studies in Heart Valve Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multiple and mixed valvular heart disease (MMVD) is a common condition in clinical practice. It corresponds to a combination of stenotic or leaky lesions on two or more heart valves (multiple valve disease), or a combination of stenotic and leaky lesions on the same valve (mixed valve disease). However, the management of their clinical, biological and cardiovascular imaging is not well established. Current European Society of Cardiology (ESC) recommendations primarily address the various valve diseases in isolation. This results in an absence of reliable recommendations for managing MMVD, with different approaches being adopted by care centres.
In order to address this knowledge gap regarding MMVD, it is crucial to assess its prevalence, the cardiovascular imaging methods employed and the management strategies, as well as to identify prognostic factors for the various combinations of valve disease.
The multicentre MMVD study will be a valuable resource as it will improve our understanding of the prognosis for patients with MMVD. It will highlight imaging and biological markers associated with the prognosis of different combinations of MMVD.
National, Prospective, Multicentric Registry. Patients with a diagnosis of MMVD identified by echocardiography will be included and followed up at 1, 2, 3, 4 and 5 years.
Patients with a diagnosis of MMVD based on cardiovascular imaging and defined as follows:
At least two cases of moderate to severe valvular heart disease, as assessed by a cardiologist and defined by transthoracic echocardiography (TTE) on one or more valves. This is in line with the recommendations of the European Society of Cardiology (ESC), the American Society of Echocardiography (ASE) and expert opinion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with a diagnosis of MMVD based on cardiovascular imaging and defined as follows: At least two cases of moderate to severe valvular heart disease, as assessed by a cardiologist and defined by transthoracic echocardiography (TTE) on one or more valves. This is in line with the recommendations of the European Society of Cardiology (ESC), the American Society of Echocardiography (ASE) and expert opinion.
To assess the association between cardiovascular imaging parameters (echocardiography and cardiac MRI) and cardiovascular event-free survival in a population of MMVD.
Survival without cardiovascular event
Time frame: 1 year after inclusion
To assess the association between cardiovascular imaging parameters and survival
Time frame: at 1, 2, 3, 4 and 5 years after inclusion
Proportion of patients who did not experience a cardiovascular event
Time frame: at 1, 2, 3, 4 and 5 years after inclusion
Proportion of patients who are alive
Time frame: at 1, 2, 3, 4 and 5 years after inclusion
Proportion of patients who did not experience a cardiovascular event depending on the type of treatment (medical, surgical or percutaneous)
Time frame: at 1, 2, 3, 4 and 5 years after inclusion
Proportion of patients who are alive depending on the type of treatment (medical, surgical or percutaneous)
Time frame: at 1, 2, 3, 4 and 5 years after inclusion
To assess the progression of the stage of severity of valvulopathy
Echocardiography
Time frame: at 1, 2, 3, 4 and 5 years after inclusion
% of patients with MMVD combinations
Time frame: during 5 years after inclusion
Measurement of cardiovascular biomarkers
BNP or NT-pro-BNP and troponin
Time frame: at baseline and 1, 2, 3, 4 and 5 years after inclusion
Assessing the association between cardiovascular biomarkers in patients with MMVD and survival
BNP or NT-pro-BNP and troponin, vital status
Time frame: during 5 years after inclusion
Assessing the association between cardiovascular biomarkers in patients with MMVD and cardiovascular event-free survival
BNP or NT-pro-BNP and troponin, Survival without cardiovascular event
Time frame: during 5 years after inclusion
Exploring the value of cardiovascular biomarkers analysed in a centralised laboratory (optional)
Biobank (optional)
Time frame: at baseline
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Oct 2028, 36 months after the start.
Of 96 non-industry observational studies under Heart Valve Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 212. This study's planned 36 months is below that.
Counting every sponsor, half of 116 studies reached it within 67 months; a quarter within 29 and three quarters within 212.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
French Cardiology Society